Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416691 | 0.98 | ALDH1A1 (0.60) | ALDH1A1EPHX1TAAR1KMT2AMEN1 | |
| SCHEMBL1414262 | 0.98 | ALDH1A1 (0.60) | ALDH1A1EPHX1TAAR1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL1414261 | 0.97 | ALDH1A1 (0.59) | ALDH1A1EPHX1TAAR1KMT2AMEN1 | |
| Cyclohexylamine SCHEMBL6680844 | 0.92 | ALDH1A1 (0.54) | ALDH1A1EPHX1TAAR1KMT2AMEN1 | |
| SCHEMBL4982451 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1MAPK1L3MBTL1 | |
| SCHEMBL15521641 | 0.85 | KEAP1 (0.48) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPK1 | |
| SCHEMBL4279441 | 0.85 | LMNA (0.52) | ALDH1A1EPHX1KMT2AMEN1KDM4E | |
| SCHEMBL5739846 | 0.84 | ACHE (0.58) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL7301279 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1GAATSHR | |
| SCHEMBL18154137 | 0.84 | ALDH1A1 (0.50) | ALDH1A1EPHX1KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850285-B | Endoperoxide compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application | 贵州大学 | 2024-08-30 | — | — | CN | disclosed |
| CN-114456180-B | Compounds and pharmaceutical formulations for the treatment and/or prophylaxis of malignant tumors and use thereof | 贵州大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-115850285-A | Endoperoxide compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application | 贵州大学 | 2023-03-28 | — | — | CN | disclosed |
| US-10723739-B2 | Processes for the preparation of Ribociclib and intermediates thereof | APOTEX INC. (CA) | 2020-07-28 | — | — | US | disclosed |
| US-10723739-B2 | Processes for the preparation of Ribociclib and intermediates thereof | APOTEX INC. (CA) | 2020-07-28 | — | — | US | disclosed |
| US-20190345163-A1 | Processes for the Preparation of Ribociclib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2019-11-14 | — | — | US | disclosed |
| US-20190345163-A1 | Processes for the Preparation of Ribociclib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2019-11-14 | — | — | US | disclosed |
| EP-1928475-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-SUBSTITUTED PRONUCLEOTIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007020193-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| EP-0813544-B1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH INC (US) | 2004-10-27 | — | — | EP | disclosed |
| CN-1150206-C | Bradykinin antagonist peptides containing N-substituted glycines | — | 2004-05-19 | — | — | CN | disclosed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | disclosed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5700779-A | ALLEVIATING PAIN, ASTHMA, INFLAMMATION, CEREBRAL EDEMA, CARDIOVASCULAR DYSFUNCTION | CORTECH, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| CN-1148393-A | Bradykinin antagonist peptides incorporating N-substituted glycines | CORTECH INC (US) | 1997-04-23 | — | — | CN | disclosed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | ALDH1A1 2212/4885EPHX1 1557/4885TAAR1 4882/4885 |
| US-10723739-B2 | Processes for the preparation of Ribociclib and intermediates thereof | RRM2B, RPIA, RTCB | ALDH1A1 863/4885EPHX1 2964/4885TAAR1 4880/4885 |
| US-20190345163-A1 | Processes for the Preparation of Ribociclib and Intermediates Thereof | RRM2B, RPIA, RTCB | ALDH1A1 863/4885EPHX1 2964/4885TAAR1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.